



Market Announcement

5 June 2020

Suda Pharmaceuticals Ltd (ASX: SUD) – Suspension from Official Quotation

Description

The securities of Suda Pharmaceuticals Ltd ('SUD') will be suspended from quotation immediately under Listing Rule 17.2, at the request of SUD, pending the release of an announcement regarding a proposed licensing transaction and a capital raising.

Issued by

Sandra Wutete
Senior Adviser, Listings Compliance (Perth)

5 June 2020

Attention: Wade Baggot
Australian Securities Exchange Limited
Level 40, Central Park
152-158 St Georges Terrace
PERTH WA 6000

Email: Wade.Baggott@asx.com.au
tradinghaltsperth@asx.com.au

Dear Wade

REQUEST FOR VOLUNTARY SUSPENSION


Suda Pharmaceuticals Ltd (ASX: SUD) (the “**Company**”) requests the securities of the Company be placed on immediate suspension in accordance with ASX Listing Rule 17.2.

The voluntary suspension is requested pending announcements by the Company to the market regarding a proposed material licensing transaction and capital raising (“**purpose**”).

In accordance with ASX Listing Rule 17.2, the Company provides the following information in relation to the request:

1. the voluntary suspension is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make announcements to the market in relation to the stated purpose;
2. the Company requests that the voluntary suspension remains in place until the earlier of commencement of normal trading on Tuesday, 9 June 2020, or when the announcements regarding the stated purpose are released to the market;
3. the Company expects to make the announcements to the market before the commencement of normal trading on Tuesday, 9 June 2020; and
4. the Company is not aware of any reason why the voluntary suspension should not be granted or of any further information necessary to inform the market about the voluntary suspension.

Yours sincerely



Joseph Ohayon
Company Secretary